Lapatinib produced by glaxosmithkline. Epidermal growth factor receptor tyrosine kinase inhibitor, an oral administration of small molecules. Mainly used for joint card of capecitabine in the treatment of erbB-2 overexpression, who previously received including anthracyclines and paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. When taking the need to pay attention to its adverse reactions.
Lapatinib in Indonesia and capecitabine combination in the treatment of breast cancer, the effect is better, and of anthracene ring antibiotics, taxanes and trastuzumab resistant patients effective, mild side effects, for advanced or metastatic breast cancer patients and a drug treatment.
Fuction and Application of Lapatinib
Lapatinib is a targeted therapy of breast cancer drug, is a tyrosine kinase inhibitor, can effectively inhibit the human epidermal growth factor receptor -1 (ErbB1) and human epidermal growth factor receptor (ErbB2) tyrosine kinase activity of -2. It is unique in that it can play a role in a variety of ways, so that breast cancer cells can not receive the signal needed for growth. The mechanism of action is to inhibit the intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites to prevent phosphorylation and activation of tumor cells, and to block the down-regulation of signaling by EGFR (ErbB-1) and HER2 (ErbB-1) homogeneous and heterogeneous two aggregates.
Molecular targeted therapy for breast cancer is the treatment of oncogenes and related expression products related to the occurrence and development of breast cancer. Molecular targeted drugs control cell gene expression by blocking the signal transduction of tumor cells or related cells, thereby inhibiting or killing tumor cells.
